2.11
Schlusskurs vom Vortag:
$2.26
Offen:
$2.22
24-Stunden-Volumen:
93,404
Relative Volume:
0.56
Marktkapitalisierung:
$140.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.6741
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
+11.05%
1M Leistung:
-10.97%
6M Leistung:
-12.81%
1J Leistung:
+11.05%
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
678-392-3419
Adresse
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Vergleichen Sie IKT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IKT
Inhibikase Therapeutics Inc
|
2.11 | 140.51M | 0 | -19.57M | -17.24M | -3.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
In wake of Anthos buyout, CFO McIntyre joins Inhibikase - BioCentury
Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks
Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com
Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN
Inhibikase Therapeutics appoints new CFO - Investing.com Australia
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire
Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India
HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria
Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire
Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks
Inhibikase enhances leadership with new appointments - Investing.com
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN
Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat
Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter
Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn
Inhibikase shelves Parkinson’s asset after Phase 2 flop - Endpoints News
Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibikase Therapeutics Inc-Aktie (IKT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):